Razoxan

Structural formula
General
Non-proprietary name	Razoxan
other names	4 - [(2 RS ) -1- (3,5-Dioxopiperazin-1-yl) propan-2-yl] piperazin-2,6-dione ( IUPAC ) ; 4 - [(±) -1- (3,5-Dioxopiperazin-1-yl) propan-2-yl] piperazin-2,6-dione;
Molecular formula	C 11 H 16 N 4 O 4
Brief description	cream colored microcrystalline powder
External identifiers / databases
EC number	244-379-2
ECHA InfoCard	100.040.330
PubChem	30623
Wikidata	Q3930720
properties
Molar mass	268.27 g mol −1
Physical state	firmly
Melting point	237-239 ° C
safety instructions
GHS labeling of hazardous substances	no GHS pictograms
	no GHS pictograms
H and P phrases	H: no H-phrases
	P: no P-phrases
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Razoxan is a racemic drug . The drug dexrazoxane is the eutomer or the dextrorotatory enantiomer , so it is 50% contained in razoxane.

chemistry

Razoxan belongs to the group of bisdioxopiperazines and is derived from piperazine .

pharmacology

As a cytostatic agent, razoxan blocks cell division between the G2 phase of the interphase and mitosis . It can support radiation therapy , especially in the case of sarcomas and gastrointestinal tumors . Various studies show that combined therapy with Razoxan is superior to radiation therapy alone.

Individual evidence

^ ^A ^b The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals , 14th Edition (Merck & Co., Inc.), Whitehouse Station, NJ, USA, 2006; P. 1399, ISBN 978-0-911910-00-1 .
↑ ^a ^b ^c Data sheet Razoxane,> 98% (HPLC) from Sigma-Aldrich , accessed on July 17, 2014 ( PDF ).
^ Kurt Hellmann, Walter Rhomberg: Razoxane and Dexrazoxane - Two Multifunctional Agents. Springer , New York a. a. 2010, p. 160, ISBN 978-90-481-9167-3 .
^ Walter Rhomberg, Josef Hammer, Felix Sedlmayer, Helmut Eiter, Dieter Seewald, Barbara Schneider: Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer. In: Radiation Therapy and Oncology. 183, 2007, pp. 380-384, doi : 10.1007 / s00066-007-1617-1 .
^ Walter Rhomberg, Franz-Karl Böhler, Hansjörg Novak, Susanne Dertinger, Gerhard Breitfellner: A Small Prospective Study of Chordomas Treated with Radiotherapy and Razoxane. In: Radiation Therapy and Oncology. 179, 2003, pp. 249-253, doi : 10.1007 / s00066-003-1052-x .

[MERCK_Index-1] A ^b The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals , 14th Edition (Merck & Co., Inc.), Whitehouse Station, NJ, USA, 2006; P. 1399, ISBN 978-0-911910-00-1 .

[Sigma-2] Data sheet Razoxane,> 98% (HPLC) from Sigma-Aldrich , accessed on July 17, 2014 ( PDF ).

[Hellmann-3] Kurt Hellmann, Walter Rhomberg: Razoxane and Dexrazoxane - Two Multifunctional Agents. Springer , New York a. a. 2010, p. 160, ISBN 978-90-481-9167-3 .

[4] Walter Rhomberg, Josef Hammer, Felix Sedlmayer, Helmut Eiter, Dieter Seewald, Barbara Schneider: Irradiation with and without Razoxane in the Treatment of Incompletely Resected or Inoperable Recurrent Rectal Cancer. In: Radiation Therapy and Oncology. 183, 2007, pp. 380-384, doi : 10.1007 / s00066-007-1617-1 .

[5] Walter Rhomberg, Franz-Karl Böhler, Hansjörg Novak, Susanne Dertinger, Gerhard Breitfellner: A Small Prospective Study of Chordomas Treated with Radiotherapy and Razoxane. In: Radiation Therapy and Oncology. 179, 2003, pp. 249-253, doi : 10.1007 / s00066-003-1052-x .